IDO1 and colorectal carcinoma: Haung et al. [139] studied the efficacy of EGFR vIII-CAR- T cells in combination with miR-153, a molecule that inhibits indoleamine 2,3-dioxygenase 1 (IDO1), which is highly expressed and inversely related to CRC patients’ survival.